ICER’s NASH Panel Shows Some Enthusiasm For Resmetirom, None For OCA

The cost-effectiveness group voted by a slight margin that Madrigal’s non-alcoholic steatohepatitis drug offers benefit above lifestyle changes alone, but decisively that Intercept’s candidate does not.